Creative Medical Technology to repurchase up to USD 2M of its shares

Creative Medical Technology Holdings, Inc., a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that its Board of Directors has approved a share repurchase program.

The program authorizes the Company to repurchase up to $2 million of its shares of common stock, in the open market or through privately negotiated transactions, in accordance with applicable securities laws and other restrictions. The manner, timing, and amount of any purchase will be based on an evaluation of market conditions, the Company’s stock price, and other factors. The program has no termination date, may be suspended or discontinued at any time, and does not obligate the Company to acquire any particular number of shares of common stock.

“Recent market uncertainty has created opportunities under which we believe the repurchase of shares of our common stock is an attractive use of our capital, particularly given our strong balance sheet,” said Timothy Warbington, President and CEO of the Company. “We feel that the company’s shares are significantly undervalued and establishing a share repurchase program at this time will maximize shareholder value.” MarketScreener